유전자 재조합 대상포진 백신 무엇이 다를까?

키워드

참고문헌 (69)

1. Chen SY, "Incidence of herpes zoster in patients with altered immune function", Infection, 42, pp.325~334 (2014)
2. Kawai K, "Increasing incidence of herpes zoster over a 60-year period from a population-based study", Clin Infect Dis, 63, pp.221~226 (2016)
3. Kawai K, "Systematic review of incidence and complications of herpes zoster : towards a global perspective", BMJ Open, 4, pp.e004833~ (2014)
4. Hope-Simpson RE, "The nature of herpes zoster : a long-term study and a new hypothesis", Proc R Soc Med, 58, pp.9~20 (1965)
5. Sahoo F, "Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies", Biol Blood Marrow Transplant, 23, pp.505~511 (2017)
6. Sullivan KM, "Myeloablative autologous stem-cell transplantation for severe scleroderma", N Engl J Med, 378, pp.35~47 (2018)
7. Muñoz-Quiles C, "Herpes zoster risk and burden of disease in immunocompromised populations : a population-based study using health system integrated databases, 2009-2014", BMC Infect Dis, 20, pp.905~ (2020)
8. Johnson BH, "Annual incidence rates of herpes zoster among an immunocompetent population in the United States", BMC Infect Dis, 15, pp.502~ (2015)
9. Choi JK, "The changing epidemiology of herpes zoster over a decade in South Korea, 2006-2015", Vaccine, 37, pp.5153~5160 (2019)
10. Jumaan AO, "Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002", J Infect Dis, 191, pp.2002~2007 (2005)
11. Thompson RR, "Herpes zoster and postherpetic neuralgia : changing incidence rates from 1994 to 2018 in the United States", Clin Infect Dis, 73, pp.e3210~e3217 (2021)
12. Drolet M, "The impact of herpes zoster and postherpetic neuralgia on health-related quality of life : a prospective study", CMAJ, 182, pp.1731~1736 (2010)
13. Hope-Simpson RE, "Postherpetic neuralgia", J R Coll Gen Pract, 25, pp.571~575 (1975)
14. Kost RG, "Postherpetic neuralgia--pathogenesis, treatment, and prevention", N Engl J Med, 335, pp.32~42 (1996)
15. Johnson RW, "Herpes zoster and its prevention by vaccination", Interdiscip Top Gerontol Geriatr, 43, pp.131~145 (2020)
16. McKay SL, "Herpes zoster risk in immunocompromised adults in the United States : a systematic review", Clin Infect Dis, 71, pp.e125~e134 (2020)
17. Choi WS, "Recommendations for adult immunization by the Korean Society of Infectious Diseases, 2023 : minor revisions to the 3rd edition", Infect Chemother, 56, pp.188~203 (2024)
18. Choi WS, "Revised adult immunization guideline recommended by the Korean Society of Infectious Diseases, 2014", Infect Chemother, 47, pp.68~79 (2015)
19. Arvin A, "Aging, immunity, and the varicella-zoster virus", N Engl J Med, 352, pp.2266~2267 (2005)
20. Takahashi M, "Live vaccine used to prevent the spread of varicella in children in hospital", Lancet, 2, pp.1288~1290 (1974)
21. Takahashi M, "Development of varicella vaccine", J Infect Dis, 197(Suppl 2), pp.S41~S44 (2008)
22. Gershon AA, "Live attenuated varicella vaccine : prevention of varicella and of zoster", J Infect Dis, 224(Suppl 2), pp.S387~S397 (2021)
23. Shapiro ED, "Effectiveness of 2 doses of varicella vaccine in children", J Infect Dis, 203, pp.312~315 (2011)
24. Oxman MN, "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults", N Engl J Med, 352, pp.2271~2284 (2005)
25. Harpaz R, "Prevention of herpes zoster : recommendations of the Advisory Committee on Immunization Practices(ACIP)", MMWR Recomm Rep, 57, pp.1~30 (2008)
26. Schmader KE, "Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years", Clin Infect Dis, 54, pp.922~928 (2012)
27. Freedman MS, "Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older-United States, 2021", MMWR Morb Mortal Wkly Rep, 70, pp.193~196 (2021)
28. Schmader KE, "Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy", Clin Infect Dis, 55, pp.1320~1328 (2012)
29. Morrison VA, "Long-term persistence of zoster vaccine efficacy", Clin Infect Dis, 60, pp.900~909 (2015)
30. Arvin AM, "Analysis of the functions of glycoproteins E and I and their promoters during VZV replication in vitro and in skin and T-cell xenografts in the SCID mouse model of VZV pathogenesis", Curr Top Microbiol Immunol, 342, pp.129~146 (2010)
31. Leroux-Roels I, "A phase 1", 2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults, 2012, pp.206, 1280~1290
32. Didierlaurent AM, "Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells", J Immunol, 193, pp.1920~1930 (2014)
33. Vandepapelière P, "Vaccine adjuvant systems containing monophosphoryl lipid A and QS21induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers", Vaccine, 26, pp.1375~1386 (2008)
34. Lal H, "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults", N Engl J Med, 372, pp.2087~2096 (2015)
35. Cunningham AL, "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older", N Engl J Med, 375, pp.1019~1032 (2016)
36. Grupping K, "Immunogenicity and safety of the HZ", su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine, 2017, pp.216, 1343~1351
37. Oostvogels L, "Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine : a pooled post-hoc analysis of two parallel randomized trials", Hum Vaccin Immunother, 15, pp.2865~2872 (2019)
38. Dooling KL, "Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines", MMWR Morb Mortal Wkly Rep, 67, pp.103~108 (2018)
39. Boutry C, "The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster : interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70", Clin Infect Dis, 74, pp.1459~1467 (2022)
40. Strezova A, "Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine : interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination", Open Forum Infect Dis, 9, pp.ofac485~ (2022)
41. Levin MJ, "Studies with herpes zoster vaccines in immune compromised patients", Expert Rev Vaccines, 16, pp.1217~1230 (2017)
42. Bastidas A, "Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation : a randomized clinical trial", JAMA, 322, pp.123~133 (2019)
43. Dagnew AF, "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies : a phase 3, randomised, clinical trial and post-hoc efficacy analysis", Lancet Infect Dis, 19, pp.988~1000 (2019)
44. Israeli E, "Adjuvants and autoimmunity", Lupus, 18, pp.1217~1225 (2009)
45. Dagnew AF, "Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases : a pooled post hoc analysis on two parallel randomized trials", Rheumatology(Oxford), 60, pp.1226~1233 (2021)
46. Stevens E, "Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients : a single center's experience with 400 patients", ACR Open Rheumatol, 2, pp.357~361 (2020)
47. Lenfant T, "Safety of recombinant zoster vaccine : a retrospective study of 622 rheumatology patients", Rheumatology(Oxford), 60, pp.5149~5157 (2021)
48. Vink P, "Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly", Hum Vaccin Immunother, 13, pp.574~578 (2017)
49. Cunningham AL, "Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older", J Infect Dis, 217, pp.1750~1760 (2018)
50. Lal H, "Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults : results of a phase III, randomized, open-label, multicenter study", Vaccine, 36, pp.148~154 (2018)
51. Hastie A, "Immunogenicity of the adjuvanted recombinant zoster vaccine : persistence and anamnestic response to additional doses administered 10 years after primary vaccination", J Infect Dis, 224, pp.2025~2034 (2021)
52. Weinberg A, "Comparative immune responses to licensed herpes zoster vaccines", J Infect Dis, 218(Suppl 2), pp.S81~S87 (2018)
53. Maréchal C, "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age : a randomized trial", Vaccine, 36, pp.4278~4286 (2018)
54. Strezova A, "The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years : a randomized trial", Vaccine, 37, pp.5877~5885 (2019)
55. MacIntyre CR, "Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old", Hum Vaccin, 6, pp.894~902 (2010)
56. Levin MJ, "Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine", Vaccine, 36, pp.179~185 (2018)
57. López-Fauqued M, "Safety profile of the adjuvanted recombinant zoster vaccine : pooled analysis of two large randomised phase 3 trials", Vaccine, 37, pp.2482~2493 (2019)
58. Callegaro A, "Association between immunogenicity and reactogenicity : a post hoc analysis of 2phase 3 studies with the adjuvanted recombinant zoster vaccine", J Infect Dis, 226, pp.1943~1948 (2022)
59. Colindres R, "Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials", Hum Vaccin Immunother, 16, pp.2628~2633 (2020)
60. "Zoster vaccine" (2023)[URL]
61. "Standards and methods for the implementation of vaccinations" (2023)[URL]
62. Yawn BP, "Herpes zoster recurrences more frequent than previously reported", Mayo Clin Proc, 86, pp.88~93 (2011)
63. Tseng HF, "The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old : incidence, complications, hospitalization, mortality, and recurrence", J Infect Dis, 222, pp.798~806 (2020)
64. Tseng HF, "Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population", J Infect Dis, 206, pp.190~196 (2012)
65. Mills R, "Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster", Vaccine, 28, pp.4204~4209 (2010)
66. Godeaux O, "Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster : a phase III, non-randomized, open-label clinical trial", Hum Vaccin Immunother, 13, pp.1051~1058 (2017)
67. "2018 guideline of adult vaccination" (2018)[URL]
68. "Zoster (herpes zoster)" (2023)[URL]
69. "Herpes zoster (shingles)vaccine: Canadian immunization guide" (2024)[URL]

관련 논문AI추천